Department of Ophthalmology, Rabin Medical Center, Petach Tikva, Israel.
Retina. 2010 Jun;30(6):938-44. doi: 10.1097/IAE.0b013e3181c96a00.
The purpose of this study was to report our experience with intravitreal bevacizumab for inflammation-related choroidal neovascularization in two tertiary centers.
This study was a retrospective analysis of patients with choroidal neovascularization related to inflammatory diseases, treated with intravitreal bevacizumab injections (1.25 mg/0.05 mL).
Ten eyes of 10 patients (range, 14-78 years; mean age, 44 years) with underlying uveitis were treated with intravitreal bevacizumab for inflammation-related choroidal neovascularization from 2006 to 2008. Mean follow-up time was 13 +/- 8 months, and the mean number of injections was 2.7 +/- 2. Resolved leakage on fluorescein angiography and resolution of subretinal fluid on optical coherence tomography occurred in all patients, with improvement in visual acuity in 9 of 10 eyes and no change in visual acuity in 1 of 10 eyes. Seven patients received additional treatment based on the underlying condition. Mean macular thickness on optical coherence tomography decreased from 394 +/- 116 microm to 254 +/- 52 microm (P < 0.01). Mean visual acuity improved from 0.87 +/- 0.74 logarithm of the minimum angle of resolution to 0.38 +/- 0.63 (P = 0.005). Seven patients reached a visual acuity of 0.2 logarithm of the minimum angle of resolution (Snellen 6/9) or better.
Intravitreal bevacizumab is an effective treatment for choroidal neovascularization related to inflammatory diseases when inflammation is controlled.
本研究旨在报告我们在两个三级中心使用玻璃体腔内贝伐单抗治疗炎症相关性脉络膜新生血管的经验。
这是一项回顾性分析，纳入了 10 例（14-78 岁；平均年龄 44 岁）因炎症性疾病导致脉络膜新生血管的患者，均接受玻璃体腔内贝伐单抗（1.25mg/0.05ml）注射治疗。
2006 年至 2008 年，10 例（10 只眼）眼后节炎症患者接受玻璃体腔内贝伐单抗治疗炎症相关性脉络膜新生血管，平均随访时间为 13±8 个月，平均注射次数为 2.7±2 次。所有患者荧光素眼底血管造影的渗漏均得到缓解，视网膜下积液均吸收，视力提高 9 只眼，无变化 1 只眼。7 例患者根据基础疾病进行了额外治疗。光学相干断层扫描（OCT）黄斑中心厚度从 394±116μm 降至 254±52μm（P<0.01），平均视力从 0.87±0.74 对数最小分辨角视力提高至 0.38±0.63（P=0.005）。7 例患者视力达到 0.2 对数最小分辨角视力（Snellen 6/9）或更好。
当炎症得到控制时，玻璃体腔内贝伐单抗是治疗炎症相关性脉络膜新生血管的有效方法。
